Article Text

AB0429 Clinical manifestations and their association with the immunological profile of primary sjögren’s syndrome
  1. S. Fernandez Nacul1,
  2. A. Secco1,
  3. M. Oliver1,
  4. M. Gauna1,
  5. D. Puente Trigo1,
  6. L. Santiago1,
  7. A. Catalan Pellet1,
  8. S. Velez1,
  9. F. Zazzetti1,
  10. J. Barreira1,
  11. D. Duarte Noe1,
  12. P. Pucci1,
  13. C. Amitrano1,
  14. C. Asnal1,
  15. A. Nitsche1,
  16. F. Cairo2,
  17. M. Haye Salinas2,
  18. L. Encinas1,
  19. O. Rillo1,
  20. S. Papasidero1,
  21. M. Tamborenea1,
  22. L. Raiti1,
  23. J. Hofman1,
  24. G. Salvatierra3,
  25. E. Albiero2
  1. 1Argentine Sjögren’s Syndrome Group of Study, Buenos Aires
  2. 2Argentine Sjögren’s Syndrome Group of Study, Cordoba
  3. 3Argentine Sjögren’s Syndrome Group of Study, Santiago del Estero, Argentina


Objectives 1-Describe the frequency of the clinical manifestations. 2- Assess their association with the antibodies anti Ro/La, ANA, Rheumatoid Factor (RF) in patients with Primary Sjögren’s Syndrome (pSS).

Methods It was analyzed the information from the GESSAR’s (Argentine Sjögren’s Syndrome Group of Study) database of patients diagnosed with pSS according to 2002 American-European criteria.

Results Out of 334 patients, 96% were women, with a median age of 57 (riq: 45-66), a median age at time of diagnosis of 52 (riq: 39-61) and a median age at onset of the symptoms of 47 (riq: 34-57), 95.78% presented xerophthalmia, 93.37% xerostomia, 32.18% parotid gland enlargement, 68.29% arthralgias, 29.58% arthritis, 8.22% purpura, 15.76% Raynaud’s disease, 5.41% pulmonary parenchymal affection, 3.60% renal affection, 9.24% peripheral neuropathy, 16.46% anemia of chronic diseases, 13.13% leukopenia and 49.36% polyclonal hypergammaglobulinemia. Anti Ro/anti La + 242/322, ANA + 264/319, RF + 138/299. In univariate analysis anti Ro/La was significantly associated with age (OR 0.98 IC95% 0.96-0.99, p<0.01), age at diagnosis (OR 0.97 IC95% 0.95-0.99, p<0.01), polyclonal hypergammaglobulinemia (OR 4.17 IC95% 1.94-8.96, p<0.01), anemia of chronic diseases (OR 2.53 IC95% 1.10-5.82, p=0.03), ANA (OR 10.93 IC95% 5.50-21.73, p<0.01), RF (OR 2.96 IC95% 1.67-5.23, p<0.01). ANA was associated with age at diagnosis (OR 0.98 IC95% 0.96-0.997, p=0.03), polyclonal hypergammaglobulinemia (OR 3.58 IC95% 1.46-8.76, p<0.01), anti /La (OR 10.93 IC95% 5.50-21.73, p<0.01), RF (OR 3.53. IC95% 1.77- 7.07, p<0.01), and RF was associated with polyclonal hypergammaglobulinemia (OR 2.65 IC95% 1.55-4.54, p<0.01), parotid gland enlargement (OR 1.82 IC95% 1.1-3.01, p=0.02), anemia of chronic diseases (OR 2.24 IC95% 1.17-2.28, p:0.02), Ro/La (OR 2.96 IC95% 1.67-5.23, p<0.01), ANA (OR 3.53 IC95% 1.77- 7.07, p<0.01). In the multivariate analysis, it was found significant and independent association between anti Ro/La and hypergammaglobulinemia (OR 3.37. IC 95% 1.50-7.55, p<0.01), age at time of diagnosis (OR 0.96. IC 95% 0.94-0.99, p<0.01) and ANA (OR 5.59 IC95% 2.25-13.88, p<0.01); the ANA remained associated with anti Ro/La (OR 9.14 IC95% 4.44-18.85, p<0.01) and with RF (OR 2.3 IC95% 1.05-5.04, p:0.04); whereas the RF was associated independently with hypergammaglobulinemia (OR 2.27 IC95% 1.30-3.96, p<0.01) and ANA (OR 4.32 IC95% 1.55-11.99, p<0.01).

Conclusions Sicca symptoms followed by arthralgias were the most frequent clinical manifestations. Hypergammaglobulinemia was the only manifestation significantly and independently associated with seropositivity for anti Ro/anti La antibodies and RF.

Disclosure of Interest None Declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.